Clinical manifestation of prostate cancer (PCa) is highly variable. Aggressive tumors require radical treatment while clinically non-significant ones may be suitable for active surveillance. We previously developed the prognostic ProstaTrend RNA signature based on transcriptome‐wide microarray and RNA-sequencing (RNA-Seq) analyses, primarily of prostatectomy specimens. An RNA-Seq study of formalin-fixed paraffin-embedded (FFPE) tumor biopsies has now allowed us to use this test as a basis for the development of a novel test that is applicable to FFPE biopsies as a tool for early routine PCa diagnostics.
%0 Journal Article
%1 rade_reliable_2024
%A Rade, Michael
%A Kreuz, Markus
%A Borkowetz, Angelika
%A Sommer, Ulrich
%A Blumert, Conny
%A Füssel, Susanne
%A Bertram, Catharina
%A Löffler, Dennis
%A Otto, Dominik J.
%A Wöller, Livia A.
%A Schimmelpfennig, Carolin
%A Köhl, Ulrike
%A Gottschling, Ann-Cathrin
%A Hönscheid, Pia
%A Baretton, Gustavo B.
%A Wirth, Manfred
%A Thomas, Christian
%A Horn, Friedemann
%A Reiche, Kristin
%D 2024
%J Molecular Medicine
%K topic_lifescience
%N 1
%P 19
%R 10.1186/s10020-024-00789-9
%T A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer
%U https://doi.org/10.1186/s10020-024-00789-9
%V 30
%X Clinical manifestation of prostate cancer (PCa) is highly variable. Aggressive tumors require radical treatment while clinically non-significant ones may be suitable for active surveillance. We previously developed the prognostic ProstaTrend RNA signature based on transcriptome‐wide microarray and RNA-sequencing (RNA-Seq) analyses, primarily of prostatectomy specimens. An RNA-Seq study of formalin-fixed paraffin-embedded (FFPE) tumor biopsies has now allowed us to use this test as a basis for the development of a novel test that is applicable to FFPE biopsies as a tool for early routine PCa diagnostics.
@article{rade_reliable_2024,
abstract = {Clinical manifestation of prostate cancer (PCa) is highly variable. Aggressive tumors require radical treatment while clinically non-significant ones may be suitable for active surveillance. We previously developed the prognostic ProstaTrend RNA signature based on transcriptome‐wide microarray and RNA-sequencing (RNA-Seq) analyses, primarily of prostatectomy specimens. An RNA-Seq study of formalin-fixed paraffin-embedded (FFPE) tumor biopsies has now allowed us to use this test as a basis for the development of a novel test that is applicable to FFPE biopsies as a tool for early routine PCa diagnostics.},
added-at = {2024-09-10T10:41:24.000+0200},
author = {Rade, Michael and Kreuz, Markus and Borkowetz, Angelika and Sommer, Ulrich and Blumert, Conny and Füssel, Susanne and Bertram, Catharina and Löffler, Dennis and Otto, Dominik J. and Wöller, Livia A. and Schimmelpfennig, Carolin and Köhl, Ulrike and Gottschling, Ann-Cathrin and Hönscheid, Pia and Baretton, Gustavo B. and Wirth, Manfred and Thomas, Christian and Horn, Friedemann and Reiche, Kristin},
biburl = {https://puma.scadsai.uni-leipzig.de/bibtex/2cea8622b46f2a1ba24246eeaaac916f0/scadsfct},
doi = {10.1186/s10020-024-00789-9},
interhash = {abdeb6c12f1d29ff802d292b8a676875},
intrahash = {cea8622b46f2a1ba24246eeaaac916f0},
issn = {1528-3658},
journal = {Molecular Medicine},
keywords = {topic_lifescience},
month = feb,
number = 1,
pages = 19,
timestamp = {2024-11-22T15:48:27.000+0100},
title = {A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer},
url = {https://doi.org/10.1186/s10020-024-00789-9},
volume = 30,
year = 2024
}
